Fig. 5: Lung targeting strategy using a STAAR permanently cationic lipid. | Communications Chemistry

Fig. 5: Lung targeting strategy using a STAAR permanently cationic lipid.

From: Multicomponent thiolactone-based ionizable lipid screening platform for efficient and tunable mRNA delivery to the lungs

Fig. 5

a Synthetic scheme used to prepare a permanent cationic lipid, namely (+) CP-LC-0729, from an ionizable lipid CP-LC-0729. b Schematic representation of the formulated LNPs incorporating a STAAR permanently cationic lipid as fifth component for mRNA delivery in vivo through i.v. administration. c Top to bottom: Ex vivo luminescence of major organs from mice, pie charts showing a profile of the tissue-specificity of mLuc expression in the lungs, heart, liver, intestine, spleen and kidneys, bar representation of total luminescence found in lungs and table with the formulation details of LNPs (n = 3 biologically independent samples). Mice were i.v. injected with mRNA-Luc-loaded LNPs at an mRNA dose of 0.2 mg/kg. Images were acquired at 4 h post-treatment. For the bar graph, data are presented as mean values ± SD. One-way ANOVA with Tukey’s correction was used.

Back to article page